Hence, anti–CTLA-4 and anti–PD-1 combination therapy allows the emergence of autoreactive B cells that recognize self antigens expressed in tissues that are targeted by irAE and also by tumor cells, which may promote antitumor responses. Here, CTLA4 is linked to neoplasm.